Phase 3 trial raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Haycocknema perplexum: [Internet]. Wildlifehealthaustralia.com.au. 2018 [cited 26 March 2018]. Available from: https://www.wildlifehealthaustralia.com.au/Portals/0/Documents/FactSheets/Public%20health/Haycocknema%20perplexum%20Mar%202008%20(1.1).pdf Albendazole [Internet]. Pubchem.ncbi.nlm.nih.gov. 2018 [cited 26 March 2018]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/albendazole#section=Top
== History == The term was first suggested in 1980, as connective tissue disease in patients whose features did not meet other classification criteria. In 1999, a study noted, "In recent years, there has been growing concern regarding the diagnosis of incomplete forms of the autoimmune diseases" and the first classification criteria were proposed in that year. Historically, the condition was sometimes called undifferentiated connective tissue syndrome, latent lupus, or incomplete lupus.
Pritzker is pro-choice and a vocal supporter of abortion rights. During the 2018 gubernatorial Democratic primaries, Planned Parenthood supported Pritzker, along with Kennedy and Biss. On January 22, 2019, Pritzker signed an executive order giving state employees and women covered under Illinois state health insurance expanded reproductive coverage, including abortion. Planned Parenthood officials praised the move and attended the signing event. In October 2023, Pritzker launched and funded the abortion rights nonprofit Think Big America, which targets ballot measures in other states as part of a broader campaign "combating far-right extremism".
Sources: en.wikipedia.org
=== Monitoring === Long-term monitoring of those with coeliac disease is an important aspect of managing the disease. Usually, someone newly diagnosed with coeliac disease is advised to visit their doctor multiple times a year, with follow-ups becoming less frequent (once or twice a year) after initial diagnosis. After the diagnosis, follow-up doctor's appointments focus on controlling symptoms, improving compliance with the GFD, preventative care, monitoring for comorbid diseases, and detection of complications. The exact testing done depends on an individual's needs but may include a complete blood count, iron panel, thyroid testing, liver enzymes, and vitamin D levels. Due to osteoporosis being a common complication of coeliac disease, bone mineral density may be tested with a DEXA scan. Although negative anti-TG2 IgA tests do not always correlate with adherence to a GFD, guidelines recommend routine testing for anti-TG2 IgA, as positive values may indicate gluten intake. The role of repeat biopsies is controversial, with studies finding little evidence that it is beneficial outside of investigating persistent symptoms Alongside routine vaccinations, current guidelines recommend pneumococcal vaccination due to increased risk of pneumonia in coeliac disease.
=== Awards received in the 2000s === COLACRO (Congreso Latinoamericano de Cromatografia) Merit Medal; Pittsburgh Analytical Chemistry Award; Eastern Analytical Symposium Award for Outstanding Achievements in the Fields of Analytical Chemistry; Tracy M. Sonneborn Award for Outstanding Research and Teaching, Indiana University; Dal Nogare Award in Chromatography; CaSSS (California Separation Science Society) Award for Excellence in Separation Science; Honorary Member of the Slovak Pharmaceutical Society; Foreign Member of the Learned Society of the Czech Republic (Czech Academy of Sciences); American Chemical Society Award in Analytical Chemistry; Jan Weber Prize and Medal, Slovak Pharmaceutical Society, Slovakia; Ralph N. Adams Award in Bioanalytical Chemistry.
High amounts of vapor particle deposition are believed to enter into the lungs with each puff because the particle size in e-cigarette vapors is within the respiratory range. After a puff, the inhaled vapor changes in the size distributions of particles in the lungs. This results in smaller exhaled particles. E-cigarette vapor is made up of fine and ultrafine particles of particulate matter. Vaping generates particulate matter 2.5 μm or less in diameter (PM2.5), but at notably less concentrations compared to cigarette smoke. Particle concentrations from vaping ranged from 6.6 to 85.0 μg/m3. Particle-size distributions of particulate matter from vaping differ across studies. The longer the puff duration the greater the amount of particles produced. The greater the amount of nicotine in the e-liquid the greater the amount of particles produced. Flavoring does not influence the particle emissions. The various kinds of devices such as cig-a-likes, medium-sized vaporizers, tanks, or mods may function at different voltages and temperatures. Thus, the particle size of the e-cigarette vapor can vary, due to the device used. Comparable to cigarette smoke, the particle size distribution mode of e-cigarette vapor ranged from 120 to 165 nm, with some vaping devices producing more particles than cigarette smoke.
Sources: en.wikipedia.org
=== Works cited === This article incorporates text from a publication now in the public domain: Chisholm, Hugh, ed. (1911). "Alum". Encyclopædia Britannica. Vol. 1 (11th ed.). Cambridge University Press. pp. 766–767.
=== The genetic code is solved === The genetic code consists of the translation of particular nucleotide sequences in mRNA to specific amino acid sequences in proteins (polypeptides). The ability to work out the genetic code emerged from the convergence of three different areas of study: (i) new methods to generate synthetic RNA molecules of defined composition to serve as artificial mRNAs, (ii) development of in vitro translation systems that could be used to translate the synthetic mRNAs into protein, and (iii) experimental and theoretical genetic work which established that the code was written in three letter "words" (codons). Today, our understanding of the genetic code permits the prediction of the amino sequence of the protein products of the tens of thousands of genes whose sequences are being determined in genome studies.
The Appalachian Mountains contain major deposits of anthracite coal as well as bituminous coal. In the folded mountains the coal is in metamorphosed form as anthracite, represented by the Coal Region of northeastern Pennsylvania. The bituminous coal fields of western Pennsylvania, western Maryland, southeastern Ohio, eastern Kentucky, southwestern Virginia, and West Virginia contain the sedimentary form of coal. The mountain top removal method of coal mining, in which entire mountain tops are removed, is currently threatening vast areas and ecosystems of the Appalachian Mountain region. The surface coal mining that started in the 1940s has significantly impacted the central Appalachian Mountains in Kentucky, Tennessee, Virginia and West Virginia. Early mining methods were unregulated and mined land reclamation research, including acid base accounting, was led by the West Virginia University in the 1960s and 1970s. West Virginia developed rigorous mine reclamation standards for state coal mines in the late 1960s. Regulations were introduced by most states to protect the Appalachian Mountains by the late 1960s. Social and political activism brought about the Surface Mining Control and Reclamation Act of 1977. The 1859 discovery of commercial quantities of petroleum in the Appalachian Mountains of western Pennsylvania started the modern United States petroleum industry. Recent discoveries of commercial natural gas deposits in the Marcellus Shale formation and Utica Shale formations have once again focused oil industry attention on the Appalachian Basin.
== Background == Cereal grains, namely porridge (and especially oatmeal), became an important breakfast component in North America. Barley was a commonly used grain, though other grains and yellow peas could be used. In many modern cultures, porridge is still eaten as a breakfast dish.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.